Skip to main content
Caplight Logo









aptaTargets

aptaTargets

Private
MadridHealthcare & Life Scienceshttps://aptatargets.com/

Last Round

Grant

Mar 11, 2024

Total Funding Raised

$16.43M

Company Overview

aptaTargets is a biopharmaceutical company that develops aptamer-based therapeutics intended to treat acute conditions driven by inflammation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

aptamer therapeuticsneuroprotective drugTLR4 antagonistischemic strokedrug licensingclinical stage biopharmaToll-like receptor 4 antagonistanti-inflammatory drugdrug discoveryintracerebral hemorrhagemyocardial infarctionGuillain-Barré syndrome

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

aptaTargets Comparables

Compare aptaTargets with similar companies based on industry and business-model similarity.

aptaTargets comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avilex Pharma
87%
NoNO Inc.
84%
FreeOx Biotech
80%

aptaTargets Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 11, 2024
GrantFeb 19, 2024
GrantJan 22, 2024
Series BOct 14, 2020
GrantJul 1, 2020
Series A
May 17, 2017

Key People

Founding team and executive leadership

Maria Eugenia Zarabozo

Co-Founder Chief Financial Officer Board Member

Founding Team

David Segarra

CEO

Executive Team

aptaTargets Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 11, 2024

    $2.7M grant awarded by the European Innovation Council.

  • Feb 19, 2024

    Secured $2M in grant funding from the Community of Madrid.

aptaTargets Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

aptaTargets Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about aptaTargets's valuation, stock price, and market status.

Firmographic Details

HeadquartersMadrid
Employee Range11
Year Founded2014
Last FundingMar 11, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?